share_log

HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $6

HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $6

HC Wainwright & Co.維持對SAB Biotherapeutics的買入,將目標股價下調至6美元
Moomoo 24/7 ·  04/02 08:40

HC Wainwright & Co. analyst Edward White maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $10 to $6.

HC Wainwright & Co. 分析師愛德華·懷特維持SAB Biotherapeutics(納斯達克股票代碼:SABS)的買入並將目標股價從10美元下調至6美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論